AlphAIAlphAI — Financial news for AI agents
pulse2.comOCT 112 min read$ANGO

AngioDynamics Q1 Revenue Rises 6.9% To $80.9 Million As Med Tech Sales Grow 13.2%

AngioDynamics reported Q1 fiscal 2027 revenue of $80.9M, up 6.9% YoY. Med Tech revenue grew 13.2% to $39.9M, while Med Device revenue rose 1.4% to $41M. Gross margin expanded to 59.4%. The company reported a GAAP net loss of $7.1M, improving from last year. Adjusted EBITDA increased to $5M. AngioDynamics reiterated its full-year revenue guidance of $336M to $341M.

Original reporting
pulse2.com
Published Oct 11, 2026, 8:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 11, 2026, 11:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Q1 Revenue Rises 6.9% To $80.9 Million As Med Tech Sales Grow 13.2% — source image
Source · pulse2.com
Decision brief

The 30-second read

$ANGONeutralMed
01

Why it matters

Earnings beat on revenue and margin expansion; guidance suggests continued growth but remains modest, likely leading to limited price movement.

02

Market read

First‑report earnings data for a micro‑cap med‑tech firm; modest trading relevance.

03

What to watch

Potential headwinds from regulatory delays or competition in NanoKnife market.

Relevance 6/10Novelty 7/10Timing: post‑market today

Background

AngioDynamics (NASDAQ: ANGO) reported Q1 2027 results, highlighting revenue growth across Med Tech, Med Device, and NanoKnife segments, and provided FY guidance.

Company-level read

Ticker impact

$ANGONeutralHigh confidence
Context

Q1 2027 earnings release with revenue up 6.9% and updated FY guidance.

Expected impact

potential modest upside as investors price in stronger top‑line and cash balance

Evidence & confidence

First‑report earnings data with improved margins and cash; guidance suggests continued growth but not a surprise breakout.

Market effects

Sector

Positive signal for med‑tech sector as AngioDynamics shows double‑digit growth.

Regional

Limited to U.S. small‑cap biotech/med‑tech investors.

Global

Low global impact; primarily affects niche medical device investors.

Counterpoint

What could challenge this read

Guidance may already be priced in; upside limited without a clear catalyst.

Key entities

  • Company
    AngioDynamics

    Medical device manufacturer reporting Q1 earnings.

Read at source← All news

Related articles

OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com2 min
OCT 14
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com2 min
OCT 14
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com2 min
OCT 9
$ANGOHigh

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

finance.yahoo.com5 min
OCT 8
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com3 min